INTRODUCTION
Retinitis pigmentosa (RP) is an unrelentingly progressive disease of the retinal photoreceptors that results in loss of visual field in the early stages and subsequently loss of visual acuity. There are currently no therapeutic agents that slow the progression of this disease, and certainly none that can restore vision in patients with RP.
Contrary to our present understanding of the incurable nature of RP, treatment with valproic acid (VPA) has recently been claimed to be beneficial in maintaining and improving the vision and visual fields of patients with this disease, based on results from a small pilot study [1] . However, the scientific rationale for using VPA to treat RP and the methodology of the study have subsequently been questioned [2, 3] .
Here we report the results from a short-term study evaluating oral VPA for the treatment of RP. The authors hypothesize that VPA acts as a chaperon and stabilizes the retinal function thereby preventing further deterioration in visual field and acuity.
MATERIALS AND METHODS
In this prospective, nonrandomized trial, 10 patients (20 eyes) with established RP received VPA 500 mg/day (Dicorate ER 500, Sun Pharmaceuticals, India; equivalent to 500 mg of divalproex sodium) for the duration of the study, which is still ongoing. The study was approved by the institution's ethics committee and conducted in accordance with the Declaration of Helsinki and good clinical practice guidelines.
Informed consent was obtained from each patient before initiating therapy. The study was conducted at a single center. Baseline investigations before the initiation of treatment included complete blood count, liver function tests, blood urea and serum creatinine estimation, and abdominal ultrasound in female patients to rule out polycystic ovarian disease.
Patients male or female above the age of 16 years were included in the study. 
RESULTS
Patients either male or female in the age group 16 years and above were included in the study. The duration and the extent of RP were not considered for the inclusion of patients in the study. None of the patients had taken any treatment before this study.
Visual Acuity
The (Fig. 1a, b) .
Visual Fields
Visual field improvement was noted in nine eyes (P\0.05, v 2 test). Nine eyes showed a significant field change, while in two eyes visual field could not be recorded at baseline or at 3 months due to poor vision (Table 1) . Three eyes, left eye of patients 1 (Fig. 2) and 5 ( Fig. 3) , and right eye of patient 10 ( Fig. 4a, b ) in which baseline fields could not be assessed due to low vision pretreatment had recordable visual fields at the end of 3 months.
DISCUSSION
Any pharmacological agent with even minimal therapeutic potential for the treatment of RP generates interest because of the lack of confirmed treatment and the inexorable progression to blindness that occurs in patients with the disease. However, newer therapies also invite considerable criticism, and it is essential to gather as much information as possible about them. Therefore, the authors share the results of their short-term study in this report.
Looking into the results of the present study, the role of VPA in stabilizing the visual field and acuity cannot be ignored. The hypothesis of it working as a chaperon and preventing the further loss of functional retina can be well noted.
While the mechanism of action of VPA in RP still remains unclear, the short-term visual gain achieved with the drug in this subset of patients is encouraging. It is unlikely that the considerable improvement in visual and documented retinal sensitivity on visual field examination are solely due to a placebo effect, particularly with the persistent and progressive visual loss as noted in most of the studies [8, 9] . It has been postulated that VPA acts as a pharmacological chaperon to increase the yield of properly folded RP mutant rhodopsins, inhibit 
Visual fields showing improvement after treatment with VPA CFCF counting fingers close to face, F female, M male, NR nonrecordable, PL perception of light, VA visual acuity, VPA valproic acid levels of histone deacetylase, and inhibit the inflammatory response pathway by the apoptosis of microglial cells [10, 11] . In addition, VPA downregulates complement proteins and increases the level of various neurotrophic factors. Together, these properties of VPA only 10 patients were analyzed and the length of follow-up was brief (an average of 3 months).
Furthermore, the patients were not genetically characterized nor was their type of RP, due to the potential role they may play in the therapeutic response.
CONCLUSION
This case series adds to the emerging knowledge on the role of VPA in the treatment of RP, meriting further study in larger groups of patients and for longer treatment periods.
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